Karyopharm Therapeutics Revenue, Growth & Competitor Profile

DBA KARYOPHARM

Company Profile & Annual Report for Karyopharm Therapeutics

Access the complete profile.

Karyopharm Therapeutics Fast Facts

Revenue	$100 - $500 million    See Exact Annual Revenue
Employees	100 - 500Exact Company Size
Primary Industry	325411 Medicinal & Botanical Manufacturing
Additional NAICS Codes	5417 Scientific Research & Development Services 541711 Research & Development in Biotechnology
Address	2nd Floor 85, Wells Avenue Newton, MA 02459

Karyopharm Therapeutics's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Karyopharm Therapeutics's annual revenues are $100 - $500 million (see exact revenue data)
• What industry is the company in?
  • Karyopharm Therapeutics is classified as operating in the Medicinal & Botanical Manufacturing industry, NAICS Code 325411.

Karyopharm Therapeutics is a publicly traded company on NMS using the ticker symbol KPTI. Detailed information on company financials and operating reports can be found here: NMS: KPTI

Karyopharm Therapeutics Annual Revenue and Growth Rate

Karyopharm Therapeutics	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2023	$100 - $500 million Details in Premium Report
2022
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Karyopharm Therapeutics's revenues are gauged from an analysis of company filings.

Investor Activity

Karyopharm Therapeutics has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.

Date	Investors	Percent Raised	Target Size
December 8, 2022	33	100%	$165 MM
Complete list of funding rounds and total amounts in the Company Report

Trademark Applications

Trademark applications show the products and services that Karyopharm Therapeutics is developing and marketing. Karyopharm Therapeutics doesn't have any recent trademark applications, indicating Karyopharm Therapeutics is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
KARYOPHARM House mark for pharmaceuticals for treatment of cancer; pharmaceuticals for treatment of life threatening diseases; pharmaceuticals for treatment of cancer	06/04/2021
XPOVI Pharmaceutical preparations, namely, drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation in humans and animals	04/28/2019
XPOVIE Pharmaceutical preparations, namely, drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation in humans and animals	04/28/2019

See all trademarks and details in the Full Report.

Market Share of Karyopharm Therapeutics's Largest Competitors

A competitive analysis shows these companies are in the same general field as Karyopharm Therapeutics, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
XYMOGEN	Orlando, FL	100
AVANTI NUTRITIONAL LABORATORIES	Miami Lakes, FL	37
NUTRITION FORMULATORS	Miramar, FL	36
RTPR	Cabot, AR	33
INTEGRATED BOTANICS	Fort Worth, TX	29
COSMAX NBT USA	Garland, TX	29
CJB INDUSTRIES	Valdosta, GA	28
ALTERNATIVE LABORATORIES	Naples, FL	28
S&B PHARMA	Azusa, CA	28

Nearby Competitors

These companies are similar in business line and location to Karyopharm Therapeutics. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
REPLIGEN	Waltham, Massachusetts,united States, MA	100
APELLIS PHARMACEUTICALS	Waltham, MA	67
CUBIST PHARMACEUTICALS	Lexington, MA	59
BIOVERATIV U.S. LLC.	Waltham, MA	58
ABCAM	Waltham, MA	29
KARYOPHARM THERAPEUTICS	Newton, MA	25

Future Competition: Karyopharm Therapeutics's Fastest Growing Competitors

These companies are in the same general field as Karyopharm Therapeutics and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)